Investment Insights
Nvidia: Underweight Until the Fog Clears
Drishtant Chakraberty, CFA, Vice President, Equity Research

Table of Contents
We are moving Nvidia to underweight. The near-term stock is now a function of a single question, not of demand, supply, or pricing: whether the board's investigation into Jensen Huang, and the parallel scrutiny of Nvidia's export licensing and its largest Singapore-based customer, surfaces evidence that Nvidia knowingly facilitated the diversion of restricted chips into China. Until that is answered, we would avoid any positive-delta instrument on the stock.
HOUSE VIEW Underweight Tactical, pending regulatory clarity | LAST CLOSE ~$172–187 Range since Nov 6, pre-scandal close | KEY DATES Nov 17 / 18 Q3 FY27 print / House briefing | RE-ENTRY LEVEL <$140 Conditional on a clean regulatory outcome |
MARKET IMPLICATIONS: WHO GAINS IF THIS DRAGS ON
A prolonged overhang, or in the adverse scenario a confirmed export-control violation, would not just compress Nvidia's multiple. It would redirect incremental AI infrastructure spending toward alternative compute and toward Nvidia's own supply chain competitors.
DIRECTION | PARTICIPANTS |
Beneficiaries | Merchant GPU alternatives led by AMD, plus the broader custom-silicon and ASIC ecosystem: Google's TPU programme, Amazon's Trainium effort, and the suppliers behind both, including Broadcom, Celestica, MediaTek, and Marvell. |
At risk | Nvidia itself, and its own supply chain, particularly the assembly and test houses and specialised component and material suppliers levered to Nvidia's shipment cadence. |
TIMELINE
— Nov 6 — NVDA closes $186.64, last print before the scandal.
— Nov 8 — Board opens independent investigation into Huang over a reported foreign-intelligence effort; Huang acknowledges a relationship with a Megaspeed executive.
— Nov 9 — Shares fall as much as 8% intraday, close ~4–5% lower; ~$300bn of market cap lost at the trough. Board says no reason to believe national security or company secrets were compromised. Huang remains CEO.
— Ongoing — Commerce's Bureau of Industry and Security had been probing Megaspeed for possible chip diversion to China; referred to the DOJ after Nvidia's counsel contacted the investigating agents. Separately, Senators Warren and Banks have asked Commerce to probe whether Huang's own past export-compliance assurances were accurate.
— Nov 12 — New reports surface a second relationship, with Nvidia health-care VP Kimberly Powell; separately reported that the board is preparing to meet on Huang's future as CEO, with his removal said to be under consideration. Unconfirmed by the company, and we would treat both strands as developing.
— Nov 17 — Nvidia reports Q3 FY27 earnings.
— Nov 18 — Closed-door House committee briefing with Huang, requested by three Republican committee chairs.
— Live — Proposed AI Overwatch Act would freeze export controls for 18 months while expanding congressional oversight of AI chip sales to China.
WHY FUNDAMENTALS DON'T DECIDE THIS
Order backlogs, Blackwell ramp economics, and hyperscaler capex all still point the same way they did a month ago, and none of it will matter if the investigating committee, Commerce, or the DOJ concludes the export-control story is real. A name trading on a governance and legal binary isn't one where a DCF earns its keep; we'd rather wait for the facts than dress up a guess as a price target.
SUCCESSION: NOT OUR CONCERN
Apple outgrew the loss of Steve Jobs under Tim Cook; Amazon's transition from Bezos to Jassy drew the same anxiety and proved just as unfounded. Nvidia has the bench and the balance sheet to name an internal interim CEO and make a considered permanent choice on its own timeline. We'd treat key-man-driven weakness in the shares as closer to a buying opportunity than a reason for caution, isolated from the regulatory question above.
THE BUSINESS CASE, AND ITS ONE CAVEAT
Nvidia looked attractive to us before this began, on the AI build-out having further to run and Nvidia's position in it remaining close to unchallenged. The sell-off has made that entry point more attractive still, purely on multiple. That view holds only for as long as Nvidia keeps executing and isn't found to have a regulatory or legal problem; if the export-control concern proves founded, we think the stock re-rates meaningfully lower from here, on a structural impairment, not a governance embarrassment.
POSITIONING
We would avoid any positive-delta instrument on the stock until the regulatory picture clears, whether that means initiating fresh long exposure or writing puts to collect premium. A clean outcome likely sees the stock reclaim and extend beyond pre-scandal levels quickly; a finding of knowing export-control violations justifies a larger, more durable de-rating than the market has priced. Once clarity emerges, our framework turns constructive: writing volatility on Nvidia and building long exposure opportunistically below $140, conditional on a favourable outcome. We will update clients as the investigation, Commerce, the DOJ, or the House committees produce anything substantive.
Disclaimer: Lighthouse Canton Pte Ltd. (“LCPL”) is incorporated in the Republic of Singapore (Registration No: 201422117K) and regulated by the Monetary Authority of Singapore (Capital Markets Services Licence No. CMS100443). Lighthouse Canton Capital (DIFC) Pte Ltd (“LCC”) is incorporated in Dubai International Financial Centre (Licence No. CL 2614) and regulated by Dubai Financial Services Authority (Category 3C Licence No. F004068). The financial products offered by LCPL and LCC are only available to Accredited Investors and Institutional Investors as defined by MAS and Professional Investors as defined by DFSA. The information in this electronic transmission does not constitute an offer, or intention by, or on behalf of LCPL and/or LCC, to subscribe, purchase or sell any financial products and/or services. LCPL and LCC accept no liability for any loss arising from the use of any information contained herein. The contents of this email are confidential and meant for the intended recipient only.

